Trial Profile

An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Nov 2018 Status changed from active, no longer recruiting to completed.
23 May 2018 Results assessing health outcoms by using data from three studies (SWORD-1, SWORD-2 and DEXA sub-study) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
12 Dec 2017 Results assessing changes at Week 48 in BMD after switching from a three-drug regimen containing tenofovir disoproxil fumarate to the NRTI-sparing dolutegravir+rilpivirine regimen, were published in the AIDS.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com